<code id='C008E6396B'></code><style id='C008E6396B'></style>
    • <acronym id='C008E6396B'></acronym>
      <center id='C008E6396B'><center id='C008E6396B'><tfoot id='C008E6396B'></tfoot></center><abbr id='C008E6396B'><dir id='C008E6396B'><tfoot id='C008E6396B'></tfoot><noframes id='C008E6396B'>

    • <optgroup id='C008E6396B'><strike id='C008E6396B'><sup id='C008E6396B'></sup></strike><code id='C008E6396B'></code></optgroup>
        1. <b id='C008E6396B'><label id='C008E6396B'><select id='C008E6396B'><dt id='C008E6396B'><span id='C008E6396B'></span></dt></select></label></b><u id='C008E6396B'></u>
          <i id='C008E6396B'><strike id='C008E6396B'><tt id='C008E6396B'><pre id='C008E6396B'></pre></tt></strike></i>

          
          WSS
          Darron Cummings/AP

          Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

          The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

          advertisement

          Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge